Vancouver, British Columbia--(Newsfile Corp. - June 27, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-approved, GMP-compliant pharmaceutical...
The Company will ship 160 doses of MDMA and psilocybin to Australian psychiatrists for the treatment of patients with PTSD and Treatment-Resistant Depression.Vancouver, British Columbia--(Newsfile Corp....
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading Health Canada licensed GMP psychedelics...
/CNW/ - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a leading Health Canada-licensed psychedelics pharmaceutical...
/CNW/ - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing...
Vancouver, British Columbia--(Newsfile Corp. - April 4, 2024) - Cathay Visions Enterprises Ltd. (the "Acquiror") acquired 110,000 common shares (each a "Common Share") of Optimi Health Corp. (the "Issuer")...
Announces the completion of its proprietary preclinical MDMA drug candidate OPTI-MHCL for use in drug ...
Announces the expansion of its sales network in Canada. To further scale the sales and distribution ...
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial plan...
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll clinical...